Anecortave Acetate Risk-Reduction Trial (AART)

Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00333216

Enrollment

Registered

2006-06-02

Start date

2005-05-31

Completion date

2008-12-31

Last updated

2012-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMD

Brief summary

The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.

Interventions

DRUGAnecortave Acetate Sterile Suspension, 30 mg/mL

Posterior juxtascleral administration of suspension

DRUGAnecortave Acetate Sterile Suspension, 60 mg/ML

Posterior juxtascleral administration of suspension

OTHERAnecortave Acetate Vehicle

Sham posterior juxtascleral administration of suspension

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Dry AMD in study eye, Wet AMD in non-study eye; * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Under 50; * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Proportion of patients with sight-threatening CNV in study eye	Month 48

Secondary

Measure	Time frame
Time to development of sight-threatening CNV	Up to 48 months
Proportion of patients with stable vision	Up to 48 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026